Clinical trials continue to be a cornerstone to the effort to advance care and improve outcomes for cancer patients. ECOG and ACRIN collectively have over 65 years of experience conducting high impact clinical trials that have helped shaped clinical practice. In response to the National Clinical Trials Network (NCTN) initiative, ECOG and ACRIN have merged their complementary scientific programs to form the ECOG-ACRIN Cancer Research Group (E-A). We propose a program focused on the efficient development and implementation of practice-changing science along the cancer care continuum from early detection through treatment of advanced disease. We take advantage of combined expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management center at the Dana Farber Cancer Institute and Brown University, to propose a portfolio of treatment and advance imaging trials that recognize the importance of biomarkers to identify appropriate patient subgroups for precisely targeted intervention. The E-A biorepositories, image database and associated translational science centers will leverage the data collected in the context of trials to perform correlative science studies that advance our understanding of cancer biology and treatment effect. We continue to seamlessly integrate with Cancer Center and SPORE research programs to create an interface for translating NCI-supported science into clinical trials and to attract junior investigators intothe NCTN. We propose to continue collaborating across the NCTN, contributing high quality trials, leadership in advance imaging, joint trial development and important NCTN operational infrastructure. E-A will leverage unique clinical informatics expertise to contribute a data warehouse of annotated images and specimens, laboratory analytics and clinical data to foster scientific discovery. E-A will contribute an accrual network of 37 main member institutions, 200 affiliates, 36 CCOPs and minority-based CCOPs that have accrued 33750 patients to clinical trials over the last 6 years. E-A is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients.
The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.
|Schneider, B P; Li, L; Shen, F et al. (2014) Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 111:1241-8|
|Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84|
|Philip, Philip A; Chansky, Kari; LeBlanc, Michael et al. (2014) Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clin Cancer Res 20:4176-85|
|Tevaarwerk, Amye J; Wang, Molin; Zhao, Fengmin et al. (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32:3948-58|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Werner, Benjamin; Gallagher, Robert E; Paietta, Elisabeth M et al. (2014) Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. Cancer Res 74:5386-96|
|Cesarman-Maus, Gabriela; Braggio, Esteban; Lome-Maldonado, Carmen et al. (2014) Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 133:606-9|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Wilson, Melissa A; Zhao, Fengmin; Letrero, Richard et al. (2014) Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 20:3328-37|
|Burtness, Barbara; Powell, Mark; Catalano, Paul et al. (2014) Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol :|
Showing the most recent 10 out of 47 publications